Total amount: € 0,00
HOW TO ORDER
A Journal on Obstetrics and Gynecology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Minerva Ginecologica 2014 December;66(6):543-9
A pharmacogenetic-driven approach for controlled ovarian hyperstimulation by FSH treatment
Colognato R. 1, 3, Aiello R. 2, Dulcetti F. 3, Ruggeri A. M. 3, De Toffol S. 3, Marcato L. 3, Irollo A. M. 2, Criscuolo C. 2, Gangale M. F. 2, Maggi F. 3, Simoni G. 3 ✉
1 GeXNano srl, Gerenzano, Varese, Italy;
2 Clinica Chianciano Salute, Chianciano Terme, Siena, Italy;
3 TOMA Advanced Biomedical Assays, Busto Arsizio, Varese, Italy
AIM: The aim of this study was to develop a pharmacogenetic- (PGx) driven approach for a controlled ovarian hyperstimulation (COH) treatment protocol used for in vitro fertilization procedures. The enrolled patients were genotyped for a single nucleotide polymorphism (SNP) N680S, within the FSHR.
METHODS: Seventy-eight women, who had previously received at least two COH cycles without positive fertilization with FSH and AMH values <10 mUI/mL and >0.3 ng/mL respectively were enrolled. They were genotyped for N680S and then categorized in high (HR), intermediate (IR), and poor responders (PR). Each subgroup received a tailored FSH treatment of 100, 225, and 400 UI/mL, respectively. The response was evaluated considering differences with previous COH cycle in terms of number of follicles (FR), oocytes (OR), and embryos produced (EMB).
RESULTS: With regards to the endpoint considered comparing the non-PGx with the PGx approach, for what regards the FR a statistically significant increase of their numbers was observed with the PGx-tailored approach (HR P<0.0001; IR P=0.00892; PR P=0.0032). Similar statistical significant results were also achieved for OR but only for HR (P<0.0001) and IR (P=0.00169). Last but not least for the EMB (HR P<0.001; IR P=0.00670 and PR P<0.0001) all the different genotype considered achieved a statistical significance.
CONCLUSION: This study, although with a limited number of enrolled patients, showed that a FSH treatment with a PGx-driven approach might have the potential to improve COH clinical outcome.